The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.

The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.

Publication date: Jan 07, 2024

The continuous evolution and mutation of SARS-CoV-2 have highlighted the need for more effective vaccines. In this study, CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines were prepared, and the immunogenicity of these vaccines in mice was evaluated. The Delta + MF59-like vaccine group produced the highest levels of S- and RBD-binding antibodies and live Delta virus neutralization levels after one shot of immunization, while mice in the Delta + Alum vaccine group had the highest levels of these antibodies after two doses, and the Delta + MF59-like and Delta + Alum vaccine groups produced high levels of cross-neutralization antibodies against prototype, Beta, and Gamma strain SARS-CoV-2 viruses. There was no significant decrease in neutralizing antibody levels in any vaccine group during the observation period. CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines excited different antibody subtypes compared with unadjuvanted vaccines; the Delta + CpG vaccine group had a higher proportion of IgG2b antibodies, indicating bias towards Th1 immunity. The proportions of IgG1 and IgG2b in the Delta + MF59-like vaccine group were similar to those of the unadjuvanted vaccine. However, the Delta + Alum vaccine group had a higher proportion of IgG1 antibodies, indicating bias towards Th2 immunity. Antigen-specific cytokine secretion CD4/8 T cells were analyzed. In conclusion, the results of this study show differences in the immune efficacy of CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines in mice, which have significant implications for the selection strategy for vaccine adjuvants.

Open Access PDF

Concepts Keywords
Beta adjuvants
Cd4 Delta
Live immunogenicity
Mice inactivated vaccines
Vaccines SARS-CoV-2

Semantics

Type Source Name
disease VO effective
disease VO vaccine
disease VO immunization
disease VO Viruses
drug DRUGBANK Coenzyme M
disease MESH COVID 19
disease MESH complications
disease MESH pneumonia
disease MESH acute respiratory distress syndrome
disease VO Glycoprotein
drug DRUGBANK Angiotensin II
disease IDO host
disease VO organization
disease MESH emergency
disease IDO history
disease VO effectiveness
disease MESH bacterial diseases
disease VO CoronaVac
disease VO COVAXIN
drug DRUGBANK Propiolactone
disease VO pregnant women
disease VO efficiency
drug DRUGBANK Aluminium
drug DRUGBANK Aluminum hydroxide
disease VO inactivation
disease VO dose
drug DRUGBANK Aspartame
disease VO volume
disease VO vaccine preparation
disease VO vaccine antigen
disease VO immunized
disease VO intraperitoneal injection
disease IDO blood
disease IDO assay
disease VO injection
disease VO vaccination
disease VO USA
disease VO titer
disease VO antibody titer
drug DRUGBANK Water
disease VO inactivated vaccine
disease VO ANOVA
disease VO vaccinated
disease MESH infection
disease IDO production
disease VO vaccine efficacy
disease IDO cell
disease IDO immune response
disease VO protection efficacy
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Guanosine
drug DRUGBANK Carboxyamidotriazole
disease VO vaccine effectiveness

Original Article

(Visited 1 times, 1 visits today)